A Pilot Study of the Immunological Effects of Neo-Adjuvant INCB024360 in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Status: Active, no longer recruiting
Phase of Trial: Phase 0
Latest Information Update: 13 Aug 2019
Price : $35 *
At a glance
- Drugs Epacadostat (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 01 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 Aug 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Mar 2016, as reported by ClinicalTrials.gov.